Polyclonal Anti-TNFRSF25

Price

200.00 USD

Size

100ug/vial

Reactivities

Hum

Format

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

References

1. Borysenko, C. W., Furey, W. F., Blair, H. C. Comparative modeling of TNFRSF25 (DR3) predicts receptor destabilization by a mutation linked to rheumatoid arthritis. Biochem. Biophys. Res. Commun. 328: 794-799, 2005.\n2. Fang, L., Adkins, B., Deyev, V., Podack, E. R. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J. Exp. Med. 205: 1037-1048, 2008.\n3. Marsters, S. A., Sheridan, J. P., Donahue, C. J., Pitti, R. M., Gray, C. L., Goddard, A. D., Bauer, K. D., Ashkenazi, A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa-B. Curr. Biol. 6: 1669-1676, 1996.\n

Storage Temp

At -20 degree C for one year. After reconstitution, at 4 degree C for one month. It can also be aliquotted and stored frozen at -20 degree C for a longer time.Avoid repeated freezing and thawing.

Scientific Background

TNFRSF25 (Tumor Necrosis Factor Receptor Superfamily Member 25), also known as LARD, APO3, DR3 or TNFR25, is a protein that in humans is encoded by the TNFRSF25 gene. Members of the mammalian tumor necrosis factor receptor (TNFR) family are cell-surface proteins that interact with a corresponding TNF-related ligand family. By fluorescence in situ hybridization, Marsters et al. (1996) mapped the Apo3 gene to 1p36.3. Marsters et al. (1996) showed that ectopic expression of Apo3 in mammalian cells triggered apoptosis and activated the transcription factor NF-kappa-B. They suggested that, like TNFR1, Apo3 may regulate distinct signaling pathways in different cellular contexts.